AnalystsCorey DavisCorey Davis's Stock Forecasts
AnalystsCorey Davis
Sectors:
Analyst Ranking
Top 32%
#1552 out of 4872 analysts
Average Return
+4.42%
Win Rate
63%10 out of 16
Risk vs Reward
Poor
Good
Corey Davis's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Nektar TherapeuticsNKTR | +161.83% | $20.25 | $53.02 | 2017-08-06 - 2018-06-11 | Buy |
Vanda Pharmaceuticals IncVNDA | +114.14% | $14.50 | $31.05 | 2018-01-18 - 2019-01-18 | Buy |
Lipocine IncLPCN | +50.98% | $26.01 | $39.27 | 2018-03-28 - 2019-03-29 | Buy |
Scynexis IncSCYX | +43.31% | $12.70 | $18.20 | 2018-04-09 - 2019-04-10 | Buy |
Pacira Biosciences IncPCRX | +33.38% | $34.75 | $46.35 | 2017-01-02 - 2018-01-03 | Buy |
Corey Davis Analyst Color
Get additional color on Corey Davis's coverage of popular stocks
Corey Davis's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Nektar TherapeuticsNKTR | 3 | Hold | $54.00 | N/A | Downgrades | 7 years ago |
Scynexis IncSCYX | 2 | Buy | $50.00 | N/A | Assumes | 7 years ago |
Vtv Therapeutics IncVTVT | 2 | Hold | $40.00 | N/A | Downgrades | 7 years ago |
Lipocine IncLPCN | 1 | Buy | $170.00 | N/A | Initiates Coverage On | 7 years ago |
Zynerba Pharmaceuticals IncZYNE | 3 | Buy | $23.00 | N/A | Assumes | 7 years ago |
Vanda Pharmaceuticals IncVNDA | 2 | Buy | $20.00 | N/A | Initiates Coverage On | 7 years ago |
Pacira Biosciences IncPCRX | 3 | Buy | $50.00 | N/A | Initiates Coverage On | 7 years ago |
Tvardi Therapeutics IncTVRD | 1 | Buy | $324.00 | N/A | Initiates Coverage On | 7 years ago |
Agile Therapeutics IncAGRX | 2 | Buy | $20,000.00 | N/A | Assumes | 8 years ago |
Jazz Pharmaceuticals PLCJAZZ | 1 | Hold | $144.00 | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.